

# Michael R Grever

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3164294/publications.pdf>

Version: 2024-02-01

85  
papers

3,297  
citations

377584

21  
h-index

162838

57  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial and socioeconomic disparities among patients with chronic lymphocytic leukemia: Analysis of Surveillance, Epidemiology, and End Results program data.. Journal of Clinical Oncology, 2022, 40, 7542-7542.	0.8	0
2	Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.. Journal of Clinical Oncology, 2022, 40, 7577-7577.	0.8	1
3	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 2021, 35, 3287-3290.	3.3	0
4	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 2021, 35, 1864-1872.	3.3	28
5	The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant. British Journal of Haematology, 2021, 193, 11-14.	1.2	12
6	Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status. Blood, 2021, 138, 1563-1563.	0.6	0
7	Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib. Blood, 2021, 138, 3731-3731.	0.6	3
8	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. American Journal of Hematology, 2020, 95, 1457-1465.	2.0	2
9	Clara D. Bloomfield, M.D. (1942-2020): Legacy in Leukemia Research. Oncologist, 2020, 25, 543-544.	1.9	0
10	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Investigational New Drugs, 2020, 38, 1400-1410.	1.2	25
11	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood, 2020, 136, 2-3.	0.6	1
12	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 22-23.	0.6	1
13	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. Blood, 2020, 136, 29-30.	0.6	1
14	Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. Blood Advances, 2019, 3, 116-118.	2.5	28
15	Biomedical Science Undergraduate Major: A New Pathway to Advance Research and the Health Professions. Teaching and Learning in Medicine, 2018, 30, 184-192.	1.3	2
16	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica, 2018, 103, 982-987.	1.7	16
17	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia and Lymphoma, 2018, 59, 1008-1011.	0.6	29
18	Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl. Blood, 2018, 132, 392-392.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. <i>Blood</i> , 2018, 132, 2305-2305.	0.6	11
20	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. <i>Blood</i> , 2018, 132, 4143-4143.	0.6	1
21	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
22	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	2.5	123
23	The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 25942-25954.	0.8	23
24	BRAF inhibitor: targeted therapy in hairy cell leukemia. <i>Blood</i> , 2016, 127, 2784-2785.	0.6	6
25	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2244-2250.	1.9	25
26	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1137-1143.	0.8	31
27	Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 265-273.	0.8	18
28	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215.	0.6	25
29	Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. <i>Haematologica</i> , 2015, 100, e18-e20.	1.7	7
30	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	1.2	8
31	The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. <i>Oncotarget</i> , 2015, 6, 2693-2708.	0.8	23
32	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. <i>Leukemia Research</i> , 2015, 39, 1270-1277.	0.4	11
33	Historical overview of hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 166-174.	0.7	11
34	Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from <i>Scytalidium album</i> . <i>Journal of Antibiotics</i> , 2015, 68, 191-196.	1.0	26
35	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	3.4	498
36	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281

#	ARTICLE	IF	CITATIONS
37	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2911-2911.	0.6	2
38	Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 3983-3983.	0.6	5
39	Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia. <i>Blood</i> , 2015, 126, 449-449.	0.6	3
40	Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. <i>Oncotarget</i> , 2015, 6, 2667-2679.	0.8	41
41	Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 9-13.	2.3	26
42	BRAFV600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation. <i>Blood</i> , 2015, 126, 2477-2477.	0.6	0
43	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 5946-5955.	3.2	72
44	Hairy cell leukemia: Update on molecular profiling and therapeutic advances. <i>Blood Reviews</i> , 2014, 28, 197-203.	2.8	35
45	Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 871-871.	0.6	11
46	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. <i>Blood</i> , 2013, 122, 2872-2872.	0.6	0
47	Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Blood</i> , 2012, 120, 3616-3616.	0.6	0
48	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood</i> , 2012, 120, 3865-3865.	0.6	0
49	How I treat hairy cell leukemia. <i>Blood</i> , 2010, 115, 21-28.	0.6	150
50	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010, 116, 2456-2456.	0.6	1
51	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. <i>Blood</i> , 2010, 116, 1378-1378.	0.6	0
52	Dedication to the clinical investigators for their work with Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1-1.	0.6	0
53	Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression.. <i>Blood</i> , 2009, 114, 1737-1737.	0.6	0
54	Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.. <i>Blood</i> , 2008, 112, 1571-1571.	0.6	1

#	ARTICLE	IF	CITATIONS
55	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. <i>Blood</i> , 2008, 112, 3169-3169.	0.6	0
56	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007, 25, 799-804.	0.8	320
57	Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 545-556.	0.7	27
58	del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.. <i>Blood</i> , 2007, 110, 2073-2073.	0.6	1
59	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. <i>Blood</i> , 2007, 110, 3104-3104.	0.6	3
60	The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL.. <i>Blood</i> , 2007, 110, 3123-3123.	0.6	1
61	Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.. <i>Blood</i> , 2007, 110, 3128-3128.	0.6	5
62	Pentostatin: Impact on Outcome in Hairy Cell Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 1099-1108.	0.9	11
63	Silvestrol, a Rocaglate Derivative from the Indonesian Plant <i>Aglaia foveolata</i> , Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2006, 108, 2600-2600.	0.6	2
64	A Phase II Study of the TNF- $\alpha$ Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.. <i>Blood</i> , 2006, 108, 2841-2841.	0.6	4
65	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. <i>Blood</i> , 2006, 108, 2845-2845.	0.6	4
66	Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.. <i>Blood</i> , 2006, 108, 302-302.	0.6	6
67	The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .. <i>Blood</i> , 2006, 108, 2833-2833.	0.6	0
68	Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.. <i>Blood</i> , 2006, 108, 2098-2098.	0.6	0
69	Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 2792-2792.	0.6	0
70	The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 2807-2807.	0.6	1
71	Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 944-944.	0.6	5
72	Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.. <i>Blood</i> , 2005, 106, 2124-2124.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 339-339.	0.6	18
74	Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 341-341.	0.6	17
75	Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.. Blood, 2004, 104, 3487-3487.	0.6	8
76	Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.. Blood, 2004, 104, 949-949.	0.6	2
77	Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.. Blood, 2004, 104, 3485-3485.	0.6	0
78	Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.. Blood, 2004, 104, 2492-2492.	0.6	9
79	Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.. Blood, 2004, 104, 476-476.	0.6	3
80	A Phase II Study of the TNF- $\alpha$ Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.. Blood, 2004, 104, 3469-3469.	0.6	1
81	The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2.. Blood, 2004, 104, 2802-2802.	0.6	0
82	Pentostatin in the treatment of hairy-cell leukemia. Best Practice and Research in Clinical Haematology, 2003, 16, 91-99.	0.7	20
83	Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia. Journal of Experimental Medicine, 2001, 194, 1639-1648.	4.2	978
84	Carboxyamido-Triazole (CAI)-a Novel $\alpha$ -Signal Transduction Inhibitor Induces Apoptosis in Human B-Cell Chronic Lymphocytic Leukemia Cells. Leukemia and Lymphoma, 2001, 42, 1049-1053.	0.6	8
85	Urinary Nucleosides in Leukemia: Laboratory and Clinical Applications. CRC Critical Reviews in Clinical Laboratory Sciences, 1986, 24, 71-93.	1.0	24